{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:03:33Z","timestamp":1769839413417,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.autrev.2020.102662","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T11:30:24Z","timestamp":1600083024000},"page":"102662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives"],"prefix":"10.1016","volume":"19","author":[{"given":"Paola","family":"Di Benedetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102662_bb0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"7","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102662_bb0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrrheum.2010.102","article-title":"Cellular and molecular aspects of vascular dysfunction in systemic sclerosis","volume":"6","author":"Trojanowska","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0015","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3899\/jrheum.150996","article-title":"Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis","volume":"43","author":"Cipriani","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0020","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1038\/s41598-019-43638-0","article-title":"Mesenchymal stem cells of systemic sclerosis patients, derived from different sources, show a profibrotic microRNA profiling","volume":"9","author":"Di Benedetto","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2020.102662_bb0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13075-014-0442-z","article-title":"Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features","volume":"16","author":"Cipriani","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102662_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13075-018-1719-4","article-title":"Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy","volume":"20","author":"Di Benedetto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102662_bb0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10456-013-9338-9","article-title":"Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine","volume":"16","author":"Cipriani","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.autrev.2020.102662_bb0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2011.04.016","article-title":"Cellular players in angiogenesis during the course of systemic sclerosis","volume":"10","author":"Cipriani","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102662_bb0045","first-page":"471","article-title":"The vessels contribute to fibrosis in systemic sclerosis","volume":"21","author":"Di Benedetto","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2020.102662_bb0050","first-page":"1488","article-title":"Linking myofibroblast generation and microvascular alteration: the role of CD248 from pathogenesis to therapeutic target (review)","volume":"20","author":"Di Benedetto","year":"2019","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2020.102662_bb0055","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in SSc is induced by the synergistic effect of ET-1 and TGF-\u03b2 and may be blocked by macitentan, a new dual ET-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","article-title":"Interstitial lung disease in systemic sclerosis: current and future treatment","volume":"37","author":"Giacomelli","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2020.102662_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.rdc.2015.04.007","article-title":"Systemic sclerosis: gastrointestinal disease and its management","volume":"41","author":"Gyger","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102662_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneph.2017.183","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"14","author":"Woodworth","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2020.102662_bb0075","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/j.ejrad.2013.02.014","article-title":"Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI)","volume":"82","author":"Di Cesare","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.autrev.2020.102662_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/ard.60.5.487","article-title":"Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)","volume":"60","author":"Matucci-Cerinic","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.imlet.2017.11.005","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis: a reset to tolerance?","volume":"195","author":"van Rhijn-Brouwer","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2020.102662_bb0095","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","article-title":"Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American society for blood and marrow transplantation","volume":"24","author":"Sullivan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0100","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10067-019-04435-2","article-title":"Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"38","author":"Guillaume-Jugnot","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0105","first-page":"165","article-title":"New therapeutic strategies for systemic sclerosis--a critical analysis of the literature","volume":"12","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2020.102662_bb0110","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jcyt.2014.12.006","article-title":"Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies","volume":"17","author":"Cipriani","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2020.102662_bb0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cei.12111","article-title":"Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy","volume":"173","author":"Cipriani","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2020.102662_bb0120","first-page":"107","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.autrev.2020.102662_bb0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cei.12985","article-title":"Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation","volume":"189","author":"Karnell","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2020.102662_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1759720X17704639","article-title":"The potential role of adult stem cells in the management of the rheumatic diseases","volume":"9","author":"Franceschetti","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0135","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/stem.2056","article-title":"Concise review: quiescence in adult stem cells\u2013biological significance and relevance to tissue regeneration","volume":"33","author":"Rumman","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.autrev.2020.102662_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaut.2018.06.002","article-title":"Hematopoietic stem cell therapy for autoimmune diseases - clinical experience and mechanisms","volume":"92","author":"Alexander","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2020.102662_bb0145","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.autrev.2012.10.004","article-title":"Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy","volume":"12","author":"Cipriani","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102662_bb0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bjh.13201","article-title":"Stem cell therapies for systemic sclerosis","volume":"168","author":"Cipriani","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102662_bb0155","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1073\/pnas.82.22.7743","article-title":"Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation","volume":"82","author":"Ikehara","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102662_bb0160","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2007-03-081497","article-title":"Reversal of autoimmune disease in lupus-prone New Zealand black\/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells","volume":"110","author":"Smith-Berdan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102662_bb0165","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1073\/pnas.86.24.10090","article-title":"Regression of adjuvant-induced arthritis in rats following bone marrow transplantation","volume":"86","author":"van Bekkum","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102662_bb0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V89.1.49","article-title":"Major histocompatibility complex restriction between hematopoietic stem cell and stromal cells in vivo","volume":"89","author":"Hashimoto","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102662_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2141.1997.3273144.x","article-title":"Haemopoietic stem cell transplantation for autoimmune diseases","volume":"99","author":"Snowden","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102662_bb0180","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2141.2004.05298.x","article-title":"Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective","volume":"128","author":"Hough","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102662_bb0185","first-page":"71","article-title":"Haematopoietic stem cell transplantation in autoimmune diseases: from basic science to clinical practice","volume":"64","author":"Kelsey","year":"2016","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.autrev.2020.102662_bb0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102662_bb0195","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009","volume":"45","author":"Ljungman","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0205","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.transproceed.2011.03.039","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients","volume":"43","author":"Song","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2020.102662_bb0210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.autrev.2017.05.020","article-title":"Hematopoietic stem cell transplantation in autoimmune disorders: From immune-regulatory processes to clinical implications","volume":"16","author":"Zeher","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102662_bb0215","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3389\/fimmu.2018.02390","article-title":"Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis","volume":"9","author":"Del Papa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102662_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4049\/jimmunol.1601100","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus","volume":"198","author":"Chaudhry","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102662_bb0225","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2020.102662_bb0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2013.202","article-title":"Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study","volume":"49","author":"Baraut","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0235","first-page":"53","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0240","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/art.21036","article-title":"Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis","volume":"52","author":"Farge","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102662_bb0245","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2016.77","article-title":"Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"51","author":"Michel","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0250","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1080\/08916930802197206","article-title":"Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages","volume":"41","author":"Brodsky","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2020.102662_bb0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2020.102662_bb0260","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1700727","article-title":"Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European league against rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Tyndall","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0265","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European group for blood and marrow transplantation working party on autoimmune diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2020.102662_bb0270","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2020.102662_bb0275","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41409-019-0430-7","volume":"54","author":"Jessop","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0280","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2020.102662_bb0285","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0290","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrrheum.2018.34","article-title":"Systemic sclerosis: autologous HSCT is efficacious, but can we make it safer?","volume":"14","author":"Burt","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/bmt.2014.251","article-title":"SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking","volume":"50","author":"Alexander","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0305","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/bmt.2012.67","article-title":"Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide","volume":"47","author":"Moore","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0310","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0315","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2003.011205","article-title":"Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT\/EULAR registry","volume":"63","author":"Farge","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0320","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1002\/art.22256","article-title":"Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens","volume":"54","author":"Burt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102662_bb0325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2005.037879","article-title":"A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease","volume":"65","author":"Tsukamoto","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0330","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0335","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2020.102662_bb0340","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis\u202f: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102662_bb0345","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0350","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1365-2141.2002.03895.x","article-title":"Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study","volume":"119","author":"Farge","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102662_bb0355","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/kel451","article-title":"Skin involvement in scleroderma--where histological and clinical scores meet","volume":"46","author":"Verrecchia","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102662_bb0360","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review","volume":"59","author":"Puyade","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102662_bb0365","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3899\/jrheum.110868","article-title":"Optimization of autologous stem cell transplantation for systemic sclerosis-a single-center long term experience in 26 patients with severe organ manifestations","volume":"39","author":"Henes","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102662_bb0370","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0375","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102662_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2020.102662_bb0385","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2020.102662_bb0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"SCOT study investigators. Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102662_bb0395","first-page":"105","article-title":"Hematopoietic stem cell transplantation","volume":"3","author":"Hatzimichael","year":"2010","journal-title":"Stem Cells Cloning"},{"key":"10.1016\/j.autrev.2020.102662_bb0400","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/annrheumdis-2019-215770","article-title":"Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures","volume":"78","author":"Assassi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0405","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3949\/ccjm.75.6.431","article-title":"Meta-analysis: its strengths and limitations","volume":"75","author":"Walker","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.autrev.2020.102662_bb0410","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0415","first-page":"116","article-title":"Stem cell transplantation for systemic sclerosis in Israel: a new star is rising","volume":"22","author":"Farge","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2020.102662_bb0420","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after nonmyeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102662_bb0425","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0430","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1704656","article-title":"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis","volume":"34","author":"Saccardi","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0435","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/1756-185X.13107","article-title":"Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset","volume":"20","author":"Giacomelli","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0440","first-page":"104","article-title":"Autologous Hematological stem cell transplantation for systemic sclerosis in Israel","volume":"22","author":"Rimar","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2020.102662_bb0445","series-title":"Field trials of health interventions: A toolbox","year":"2015"},{"key":"10.1016\/j.autrev.2020.102662_bb0450","first-page":"566","article-title":"Opportunities and pitfalls in the definition of data validity","volume":"247","author":"Stausberg","year":"2018","journal-title":"Stud Health Technol Inform"},{"issue":"suppl_5","key":"10.1016\/j.autrev.2020.102662_bb0455","doi-asserted-by":"crossref","first-page":"v53","DOI":"10.1093\/rheumatology\/kex202","article-title":"Assessment of skin involvement in systemic sclerosis","volume":"56","author":"Kum\u00e1novics","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102662_bb0460","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102662_bb0465","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102662_bb0470","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102662_bb0475","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/bmt.2016.126","article-title":"Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?","volume":"51","author":"Oliveira","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","article-title":"CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2020.102662_bb0485","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/art.37969","article-title":"Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies","volume":"65","author":"Onishi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102662_bb0490","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/bmt.2014.325","article-title":"Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation \u2014 systematic review and meta-analysis","volume":"50","author":"Vaxman","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2020.102662_bb0495","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2020.102662_bb0500","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bmt.1704763","article-title":"Cardiac toxicity of high-dose chemotherapy","volume":"35","author":"Morandi","year":"2005","journal-title":"Bone Marrow Transplant"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:41Z","timestamp":1761599921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1568997220302378"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102662","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102662"}}